Divergence Labs Preprint Claims Claude-Designed Antibody Removes Receptor-Bound IgE

Divergence Labs has published a preprint, dated 29 October 2026, describing an agentic computational design campaign run with Claude. The company says its antibody candidate physically removes IgE already bound to the FcεRI receptor, a mechanism it contrasts with Omalizumab (Xolair), which neutralizes circulating IgE. The preprint is the company's own technical account, aimed at food allergy.